Cytokines have a myriad role in an infectious disease, whether being pathogenic, bacterial, or viral. All proinflammatory and anti-inflammatory cytokine biological function are dependent on its concentration, followed by combination with the other cytokines and the stage of the disease. Plasticity in switching off from one phenotype to the other of these regulatory mediators in congruence with the traditional concept of inhibitory and stimulatory effects on immune system is dealt with. This review highlights the dual functionality of some of these cytokines and cytokine-based immunotherapy.
ApteRN, VoronovE. 2008. Is interleukin-1 a good or bad “guy” in tumor immunobiology and immunotherapy?. Immunol Rev, 222(1):222–241.
3.
AshkarAA, ReidS, VerduEF, ZhangK, CoombesBK. 2009. Interleukin-15 and NK1.1+ cells provide innate protection against acute Salmonella enterica serovar Typhimurium infection in the gut and in systemic tissues. Infect Immun, 77(1):214–222.
4.
BanerjeeA, BhattacharyaP, JoshiAB, IsmailN, DeyR, NakhasiHL. 2016. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol, 309:37–41.
5.
BarryKC, FontanaMF, PortmanJL, DuganAS, VanceRE. 2013. IL-1alpha signaling initiates the inflammatory response to virulent Legionella pneumophila in vivo. J Immunol, 190:6329–6339.
6.
BerrettaF, St-PierreJ, PiccirilloCA, StevensonMM. 2011. IL-2 contributes to maintaining a balance between CD4+ Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection. J Immunol, 186:4862–4871.
7.
BickelM. 1993. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol, 64 (5 Suppl.):456–460.
8.
BosmannM, WardPA. 2013. Modulation of inflammation by interleukin-27. J Leukoc Biol, 94(6):1159–1165.
ChangKH, KimJM, KimHY, SongYG, ChoiYH, ParkYS, ChoJH, HongSK. 2000. Spontaneous programmed cell death of peripheral blood mononuclear cells from HIV-infected persons is decreased with interleukin-15. Yonsei Med J, 41(1):112–118.
11.
ChenCY, HuangD, YaoS, HallidayL, ZengG, WangRC, ChenZW. 2012. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol, 188:4278–4288.
12.
ChungY, ChangSH, MartinezGJ, YangXO, NurievaR, KangHS, et al.2009. Critical regulation of early Th17 cell differentiation by IL-1 signaling. Immunity, 30(4):576–587.
13.
CollinsJW, KeeneyKM, CrepinVF, RathinamVA, FitzgeraldKA, FinlayBB, FrankelG. 2014. Citrobacter rodentium: infection, inflammation and the microbiota. Nat Rev Microbiol, 12(9):612.
14.
DasS, KhaderS. 2017. Yin and yang of interleukin-17 in host immunity to infection. F1000Res, 6:741.
15.
Di SabatinoA, CalarotaSA, VidaliF, MacDonaldTT, CorazzaGR. 2011. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev, 22(1):19–33.
16.
DinarelloCA. 2001. Anti-cytokine therapies in response to systemic infection. J Invest Dermatol Symp Proc, 6(3):244–250.
17.
DinarelloCA. 2003. Anti-cytokine therapeutics and infections. Vaccine, 21:S24–S34.
18.
DinarelloCA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 117(14):3720–3732.
19.
DivanovicS, TrompetteA, AshworthJI, RaoMB, KarpCL. 2011. Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis, 5(9):e1316.
20.
ErdmannH, RoßnagelC, BöhmeJ, IwakuraY, JacobsT, SchaibleUE, HölscherC. 2013. IL-17A promotes macrophage effector mechanisms against Trypanosoma cruzi by trapping parasites in the endolysosomal compartment. Immunobiology, 218(6):910–923.
21.
EspirTT, de Paula FigueiraL, de Farias NaiffM, da CostaAG, Ramalho-OrtigãoM, MalheiroA, et al.2014. The role of inflammatory, anti-inflammatory, and regulatory cytokines in patients infected with cutaneous leishmaniasis in amazonas state, Brazil. J Immunol Res, 2014:10.
22.
FerenciP. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C. 2003. Int J Clin Pract, 57(7):610–615.
23.
FernandesJR, BerthoudTK, KumarA, AngelJB. 2017. IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: implications for persistent immune activation. PLoS One, 12(11):e0186823.
24.
FlierlMA, RittirschD, GaoH, HoeselLM, NadeauBA, DayDE, WardPA. 2008. Adverse functions of IL-17A in experimental sepsis. FASEB J, 22(7):2198–2205.
25.
FranzAR, SteinbachG, KronM, PohlandtF. 2001. Interleukin-8: a valuable tool to restrict antibiotic therapy in newborn infants. Acta Paediatr, 90(9):1025–1032.
26.
FujioK, OkamuraT, SumitomoS, YamamotoK. 2015. Therapeutic potential of regulatory cytokines that target B cells. Int Immunol, 28(4):189–195.
27.
GaffenSL. 2009. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol, 9(8):556.
28.
GhiasiH, CaiS, SlaninaSM, PerngGC, NesburnAB, WechslerSL. 1999. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis, 179(5):1086–1093.
29.
GideonHP, FlynnJL. 2016. Characterization of immunomodulatory cytokine IL-27 in tuberculosis infection. J Immunol, 196(1):206.
30.
HalwaniR, BoyerJD, Yassine-DiabB, HaddadEK, RobinsonTM, KumarS, PavlakisGN. 2008. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA+ IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol, 180(12):7969–7979.
31.
HammondME, LapointeGR, FeuchtPH, HiltS, GallegosCA, GordonCA, et al.1995. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol, 155(3):1428–1433.
32.
HannaWJ, BerrensZ, LangnerT, LahniP, WongHR. 2015. Interleukin-27: a novel biomarker in predicting bacterial infection among the critically ill. Crit Care, 19(1):378.
33.
HsuD, TaylorP, FletcherD, van HeeckerenR, EastmanJ, van HeeckerenA, BonfieldTL. 2016. Interleukin-17 pathophysiology and therapeutic intervention in cystic fibrosis lung infection and inflammation. Infect Immun, 84(9):2410–2421.
34.
HübelK, DaleDC, LilesWC. 2002. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-γ. J Infect Dis, 185(10):1490–1501.
35.
INSIGHT–ESPRIT Study Group, SILCAAT Scientific Committee. 2009. Interleukin-2 therapy in patients with HIV infection. N Engl J Med, 361(16):1548–1559.
36.
IsailovicN, DaigoK, MantovaniA, SelmiC. 2015. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun, 60:1–11.
37.
JabbariA, HartyJT. 2006. Secondary memory CD8+ T cells are more protective but slower to acquire a central–memory phenotype. J Exp Med, 203(4):919–932.
JonaschE, HaluskaFG. 2001. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The Oncologist, 6(1):34–55.
40.
JonesSA, SchellerJ, Rose-JohnS. 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest, 121(9):3375–3383.
41.
JuffermansNP, FlorquinS, CamoglioL, VerbonA, KolkAH, SpeelmanP, Van der PollT. 2000. Interleukin-1 signaling is essential for host defense during murine pulmonary tuberculosis. J Infect Dis, 182(3):902–908.
42.
KeestraAM, GodinezI, XavierMN, WinterMG, WinterSE, TsolisRM, BäumlerAJ. 2011. Early, MyD88-dependent induction of interleukin-17A expression during Salmonella colitis. Infect Immun, 79(8):3131–3140.
43.
KimizukaY, KimuraS, SagaT, IshiiM, HasegawaN, BetsuyakuT, YamaguchiK. 2012. Roles of interleukin-17 in an experimental Legionella pneumophila pneumonia model. Infect Immun, 80(3):1121–1127.
KimuraD, MiyakodaM, HonmaK, ShibataY, YudaM, ChinzeiY, YuiK. 2010. Production of IFN-γ by CD4+ T cells in response to malaria antigens is IL-2 dependent. Int Immunol, 22(12):941–952.
46.
KruegerM, NauckMS, SangS, HentschelR, WielandH, BernerR. 2001. Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants. Neonatology, 80(2):118–123.
47.
LaneBR, LoreK, BockPJ, AnderssonJ, CoffeyMJ, StrieterRM, MarkovitzDM. 2001. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J Virol, 75(17):8195–8202.
48.
LangleyRG, ElewskiBE, LebwohlM, ReichK, GriffithsCE, PappK, RivasE. 2014. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med, 371(4):326–338.
49.
LeeBH, CarcamoWC, ChioriniJA, PeckAB, NguyenCQ. 2012. Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy. Arthritis Res Ther, 14(4):R172.
50.
LeonardoMJ. 1996. Fas and the art of lymphocyte maintenance. J Exp Med, 183:721–724.
51.
LinKJ, LinJ, HanasawaK, TaniT, KodamaM. 2000. Interleukin-8 as a predictor of the severity of bacteremia and infectious disease. Shock, 14(2):95–100.
52.
LockhartE, GreenAM, FlynnJL. 2006. IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol, 177(7):4662–4669.
53.
LustJA, LacyMQ, ZeldenrustSR, DispenzieriA, GertzMA, WitzigTE, GeyerSM. 2009. Induction of a chronic disease states in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. In Mayo Clin Proc, 84(2):114–122.
54.
MacLennanC, FieschiC, LammasDA, PicardC, DormanSE, SanalO, KumararatneDS. 2004. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis, 190(10):1755–1757.
55.
MalekTR, BayerAL. 2004. Tolerance, not immunity, crucially depends on IL2. Nat Rev Immunol, 4:665–674.
56.
MarchCJ, MosleyB, LarsenA, CerrettiDP, BraedtG, PriceV, et al.1985. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature, 315:641–647.
57.
Marks-KonczalikJ, DuboisS, LosiJM, et al.2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A, 97:11445–11450.
58.
McGeachyMJ, Bak-JensenKS, ChenYI, TatoCM, BlumenscheinW, McClanahanT, CuaDJ. 2007. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T H-17 cell–mediated pathology. Nat Immunol, 8(12):1390.
59.
MesserJ, EyerD, DonatoL, GallatiH, MatisJ, SimeoniU. 1996. Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr, 129(4):574–580.
60.
MillerLS, O'ConnellRM, GutierrezMA, PietrasEM, ShahangianA, GrossCE, et al.2006. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity, 24:79–91.
61.
ModyCH, SpurrellJC, WoodCJ. 1998. Interleukin-15 induces antimicrobial activity after release by Cryptococcus neoformans-stimulated monocytes. J Infect Dis, 178(3):803–814.
62.
MurphyAG, O'KeeffeKM, LalorSJ, MaherBM, MillsKH, McLoughlinRM. 2015. Staphylococcus aureus infection of mice expands a population of memory γδ T cells that are protective against subsequent infection. J Immunol, 194(9):4588.
63.
NaritaM, TanakaH, YamadaS, AbeS, ArigaT, SakiyamaY. 2001. Significant role of interleukin-8 in pathogenesis of pulmonary disease due to Mycoplasma pneumoniae infection. Clin Diagn Lab Immunol, 8(5):1028–1030.
64.
NgPC, ChengSH, ChuiKM, FokTF, WongMY, WongW, CheungKL. 1997. Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child Fetal Neonatal Ed, 77(3):F221–F227.
NoguchiM, NakamuraY, RussellSM, et al.1993. Interleukin-2 receptor chain: a functional component of the interleukin-7 receptor. Science, 262:1877–1880.
67.
OkadaM, KitaY, KanamaruN, HashimotoS, UchiyamaY, MiharaM, SakataniM. 2011. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-?? antibody in mice. Clin Dev Immunol, 2011:404929.
68.
OliveiraPR, DesseinH, RomanoA, CabantousS, de BritoME, SantoroF, et al.2015. IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis. J Immunol, 194(6):2664–2672.
69.
O'MearaCP, ArmitageCW, HarvieMC, AndrewDW, TimmsP, LyckeNY, BeagleyKW. 2014. Immunity against a Chlamydia infection and disease may be determined by a balance of IL-17 signaling. Immunol Cell Biol, 92(3):287–297.
70.
OppmannB, LesleyR, BlomB, TimansJC, XuY, HunteB, VegaF, YuN, WangJ, SinghK, ZoninF, VaisbergE, ChurakovaT, LiuM, GormanD, WagnerJ, ZurawskiS, LiuY, AbramsJS, MooreKW, RennickD, de Waal-MalefytR, HannumC, BazanJF, KasteleinRA. 2001. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13:715–725.
71.
PanHF, TaoJH, YeDQ. 2010. Therapeutic potential of IL-27 in systemic lupus erythematosus. Expert Opin Ther Targets, 14(5):479–484.
72.
ParhamC, ChiricaM, TimansJ, VaisbergE, TravisM, CheungJ, PflanzS, ZhangR, SinghKP, VegaF, ToW, WagnerJ, O'FarrellAM, McClanahanT, ZurawskiS, HannumC, GormanD, RennickDM, KasteleinRA, de Waal MalefytR, MooreKW. 2000. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol, 168(11):5699–5708.
73.
PavlakisG, BergamaschiC, ValentinA, KulkarniV, JalahR, RosatiM, FelberB. 2015. Use of heterodimeric IL-15 in immune therapeutic regimens against HIV-1 or SIV infection (VAC8P. 1048). J Immunol, 194(1):144–148.
74.
PeckhamRK, BrillR, FosterDS, BowenAL, LeighJA, CoffeyTJ, FlynnRJ. 2014. Two distinct populations of bovine IL-17+ T-cells can be induced and WC1+ IL-17+ γδ T-cells are effective killers of protozoan parasites. Sci Rep, 4:5431.
RobinsonCM, NauGJ. 2008. Interleukin-12 and interleukin-27 regulate macrophage control of Mycobacterium tuberculosis. J Infect Dis, 198(3):359–366.
80.
RossiJF, LuZY, JourdanM, KleinB. 2015. Interleukin-6 as a therapeutic target. Clin Cancer Res, 21(6):1248–1257.
81.
SaadounD, RosenzwajgM, JolyF, SixA, CarratF, ThibaultV, SeneD, CacoubP, KlatzmannD. 2011. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med, 365:2067–2077.
82.
SadeghiM, LahdouI, OpelzG, MehrabiA, ZeierM, SchnitzlerP, DanielV. 2016. IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients. BMC Immunol, 17(1):35.
SananezI, RaidenS, Erra-DíazF, De LilloL, HolgadoMP, GeffnerJ, ArruvitoL. 2018. Dampening of IL-2 function in infants with severe respiratory syncytial virus disease. J Infect Dis, 218(1):75–83.
85.
SandauMM, KohlmeierJE, WoodlandDL, JamesonSC. 2010. IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool. J Immunol, 184(1):35–44.
86.
SchellerJ, ChalarisA, Schmidt-ArrasD, Rose-JohnS. 2011. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta, 1813(5):878–888.
87.
SchinkeC, GiriczO, LiW, ShastriA, GordonS, BarreyroL, PellagattiA. 2015. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood, 125(20):3144–3152.
88.
ScottLJ. 2017. Tocilizumab: a review in rheumatoid arthritis. Drugs, 77(17):1865–1879.
89.
SekiguchiY, YasuiK, YamazakiT, AgematsuK, KobayashiN, KoikeK. 2005. Effective combination therapy using interferon-γ and interleukin-2 for disseminated Mycobacterium avium complex infection in a pediatric patient with AIDS. Clin Infect Dis, 41(11):e104–e106.
ShenF, LiY, WangY, SozziV, RevillPA, LiuJ, GaoL, YangG, LuM, SutterK, DittmerU. 2018. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype. Hepatology, 67(4):1237–1252.
92.
SoniB, SahaB, SinghS. 2018. Systems cues governing IL6 signaling in leishmaniasis. Cytokine, 106:169–175.
93.
SteelJC, WaldmannTA, MorrisJC. 2012. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci, 33(1):35–41.
94.
StrleK, StupicaD, DrouinEE, SteereAC, StrleF. 2013. Elevated levels of IL-23 in a subset of patients with post–Lyme disease symptoms following erythema migrans. Clin Infect Dis, 58(3):372–380.
95.
SuzukiH, TakahashiY, WatayaH, IkedaK, NakabayashiS, ShimomuraA, TakasakaT. 1996. Mechanism of neutrophil recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin Immunol, 98(3):659–670.
96.
SwaminathanS, DaiL, LaneHC, ImamichiT. 2013. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. Cytokine Growth Factor Rev, 24(6):571–577.
97.
TorradoE, FountainJJ, LiaoM, TigheM, ReileyWW, LaiRP, ThompsonEG. 2015. Interleukin 27R regulates CD4+ T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection. J Exp Med, 212(9):1449–1463.
Troye-BlombergM, AnderssonG, StoczkowskaM, ShaboR, RomeroP, PatarroyoME, PerlmannP. 1985. Production of IL 2 and IFN-gamma by T cells from malaria patients in response to Plasmodium falciparum or erythrocyte antigens in vitro. J Immunol, 135(5):3498–3504.
100.
UlloaL, TraceyKJ. 2005. The “cytokine profile”: a code for sepsis. Trends Mol Med, 11(2):56–63.
101.
UsmaniSS, BediG, SamuelJS, SinghS, KalraS, KumarP, AhujaAA, SharmaM, GautamA, RaghavaGP. 2017. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS One, 12(7):e0181748.
102.
VázquezN, WalshTJ, FriedmanD, ChanockSJ, LymanCA. 1998. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect Immun, 66(1):145–150.
103.
VogelsMT, ElingWM, OttenA, Van Der MeerJW. 1995. Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor. Antimicrob Agents Chemother, 39(8):1744–1747.
104.
von StebutE, EhrchenJM, BelkaidY, KostkaSL, MölleK, KnopJ, et al.2003. Interleukin 1α promotes Th(1) differentiation and inhibit disease progression in Leishmania major—susceptible BALB/c mice. J Exp Med, 98(2):191–199.
105.
WaldmannTA. 2002. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol, 22(2):51–56.
106.
WaldmannTA, DuboisS, TagayaY. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes; implications for immunotherapy. Immunity, 14:105–110.
WarfelJM, MerkelTJ. 2013. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol, 6(4):787.
109.
WeitkampJH, ReinsbergJ, BartmannP. 2002. Interleukin-8 (IL-8) preferable to IL-6 as a marker for clinical infection. Clin Diagn Lab Immunol, 9(6):1401.
YajimaT, YoshiharaK, NakazatoK, KumabeS, KoyasuS, SadS, YoshikaiY. 2006. IL-15 regulates CD8+ T cell contraction during primary infection. J Immunol, 176(1):507–515.
112.
YoshidaYO, UmemuraM, YahagiA, O'BrienRL, IkutaK, KishiharaK, MatsuzakiG. 2010. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol, 184:4414–4422.
113.
ZagoCA, BortoluciKR, SardinhaLR, PretelFD, Castillo-MéndezSI, do RosárioAPF, ÁlvarezJM. 2012. Anti-IL-2 treatment impairs the expansion of Treg cell population during acute malaria and enhances the Th1 cell response at the chronic disease. PLoS One, 7(1):e29894.
114.
ZhuJ, YamaneH, PaulWE. 2010. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol, 28:445–489.
